Skip to Main Content

Paper Details

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
Nat Med
56
2021
Mesothelioma, Patients, PrE0505, T cell repertoire, anti-PD-L1 antibody, cancer, cancer predisposing genes, cisplatin, malignant pleural mesothelioma, patients, pemetrexed, platinum, pleural mesothelioma, tumors
Author NameAffiliation
Rachel KarchinThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Rachel KarchinInstitute for Computational Medicine, Johns Hopkins University
Rachel KarchinJohns Hopkins University
Rachel KarchinThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Rachel KarchinInstitute for Computational Medicine, Johns Hopkins University
Rachel KarchinJohns Hopkins University
Victor E VelculescuThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Victor E VelculescuThe Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine
Victor E VelculescuJohns Hopkins University
Victor E VelculescuJohns Hopkins University School of Medicine
  • 1 - 10

Datasets

Release 1.2